A first-in-human study of the SUMOylation Inhibitor Subasumstat in patients with advanced/metastatic solid tumors or relapsed/refractory hematologic malignancies 2025

Validation of immunotherapy response score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit 2023